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Abstract
Abnormalities in adrenal and/or ovarian steroidogenesis are found
in most patients with hirsutism. The rate-limiting step in the syn-
thesis of steroids in the ovary and the adrenal is the conversion of
cholesterol into pregnenolone by cholesterol side-chain cleavage en-
zyme (P450scc), encoded by the gene CYP11A, after cholesterol is
introduced into the mitochondria by the steroidogenic acute regula-
tory protein (StAR). DAX-1 is a repressor of StAR gene expression,
and steroidogenic factor-1 (SF-1) is a regulator of CYP11A, DAX-1,
and StAR gene. Mutations in any of these factors resulting in gain of
function, or loss of repression, of StAR or P450scc might contribute to
the steroidogenic abnormalities present in hirsute patients.
In the present study we have screened, using heteroduplex anal-
ysis, the genes encoding StAR and SF-1 as well as DAX-1 and CYP11A
for mutations in genomic DNA from 19 women presenting with hir-
sutism and increased serum androgen levels. When variants were
found, analysis was extended to a larger group of hyperandrogenic
patients and nonaffected women. Two variants were identified in the
SF-1 gene. A G3C change in exon 6, resulting in an Arg365Pro mu-
tation, was found in 1 of 45 patients, but not in controls. Also, a
Gly146Ala missense mutation, resulting from a G3C change in exon
4, was found in 2 of 48 patients and in 2 of 50 nonaffected individuals.
We identified a C3T base pair change at position 233 of the StAR
gene. Three of 48 patients and 3 of 43 controls presented this variant.
No mutations were found in coding regions of the StAR gene. Analysis
of CYP11A-coding regions identified a G3A change in exon 3, re-
sulting in a Val179Ile missense mutation. This mutation was found in
1 of 29 patients studied and was not present in 50 controls. Finally,
analysis of DAX-1 showed no variant in any of the women studied.
In conclusion, mutations in StAR, SF-1, CYP11A, and DAX-1 are
seldom found in hirsute patients and do not explain the steroidogenic
abnormalities found in these women. (J Clin Endocrinol Metab 86:
1746–1749, 2001)
FAMILIAL AGGREGATION provides evidence pointing toa genetic basis of hyperandrogenism in women (1), es-
pecially in the polycystic ovary syndrome (PCOS), in which
clinical and/or biochemical hyperandrogenism is associated
with ovulatory dysfunction (2). However, there is also familial
aggregation of cases of women presenting with hyperandro-
genism who do not have ovulatory dysfunction (1).
Hirsutism results from androgen excess at the piloseba-
ceous unit and is considered a clinical marker of hyperan-
drogenism in women. In nearly all hirsute women, abnor-
malities in adrenal and/or ovarian steroidogenesis can be
demonstrated, suggesting that both glands contribute to
some extent to the androgen excess responsible for hirsutism
(3, 4).
The enzymes required for the synthesis of androgens are
cholesterol side-chain cleavage enzyme (P450scc), encoded
by the gene CYP11A; P450c17, encoded by CYP17; 3b-
hydroxysteroid dehydrogenase; and several isoenzymes of
17b-hydroxysteroid dehydrogenase. The adrenal and the
ovary share most of these enzymes. Moreover, the activities
of P450scc, P450c17, 3b-hydroxysteroid dehydrogenase, and
17b-hydroxysteroid dehydrogenase type 5 are increased in
thecal cells from PCOS patients maintained in primary cul-
ture, an abnormality that can be considered a primary event
in the pathogenesis of this disorder (5, 6).
The genes encoding for the enzymes involved in an-
drogen synthesis have been studied in women with hy-
perandrogenism, but no definite role for any of the vari-
ants found has been established to date. Polymorphisms in
the regulatory regions of CYP11A and CYP17 do not ap-
pear to be related to hyperandrogenism (7–10). The coding
regions of CYP11A have not been studied, and the exis-
tence of nonclassical 3b-hydroxysteroid dehydrogenase
deficiency has never been demonstrated at the molecular
genetic level (11). Furthermore, no association of variants
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in any of the genes encoding the 17b-hydroxysteroid de-
hydrogenase isoenzymes with hyperandrogenism have
been reported to date. Therefore, the genes encoding other
factors involved in the regulation of adrenal and ovarian
androgen synthesis should be considered candidates to
explain the etiology of hyperandrogenism.
The initial step in adrenal and ovarian androgen synthesis
is the conversion of cholesterol to pregnenolone. This con-
version is catalyzed by the mitochondrial enzyme P450scc
and requires transport of cholesterol into the mitochondria,
which is mediated by the steroidogenic acute regulatory
protein (StAR). Dosage-sensitive sex reversal-adrenal hyp-
oplasia gene on the X chromosome gene-1 (DAX-1) is a re-
pressor of StAR gene expression, and steroidogenic factor-1
(SF-1) is a regulator of StAR gene, CYP11A, and DAX-1,
among others.
Recently, it has been shown that inactivating mutations in
DAX-1 and StAR genes are the cause of adrenal hypoplasia
congenita and lipoid congenital adrenal hyperplasia, respec-
tively (12, 13), and an inactivating mutation in SF-1 resulted
in sex reversal and adrenal failure in a 46,XY subject (14). To
date, inactivating CYP11A mutations have not been
described.
Conversely, variants in the genes encoding for these fac-
tors, resulting in gain of function, or loss of repression, of
StAR, P450scc, or other steroidogenic enzymes, might con-
tribute to androgen excess in hyperandrogenic women. To
test this hypothesis, we have screened the genes encoding
StAR, SF-1, DAX-1, and CYP11A for mutations in genomic




Nineteen hyperandrogenic hirsute women [mean 6 sd: age, 22.3 6
6.2 yr; body mass index, 26.7 6 6.8 kg/m2; modified Ferriman-Gallwey
score (15), 17.1 6 5.3] were initially screened for mutations.
Serum samples were obtained during the follicular phase of the
menstrual cycle. All of the patients presented hyperandrogenemia, as
defined by increased serum concentrations of one or more of the fol-
lowing androgens: total testosterone above 2.30 nmol/L, calculated free
testosterone (16) above 35 pmol/L, androstenedione above 16.0 nmol/L,
and dehydroepiandrosterone sulfate above 9.9 mmol/L. The mean 6 sd
circulating levels of these androgens were 2.9 6 1.4 nmol/L, 61 6 52
pmol/L, 12.8 6 4.5 nmol/L, and 9.7 6 4.7 mmol/L, respectively. The
assays employed for serum hormone measurements have been reported
previously (17).
Nonclassical congenital adrenal hyperplasia and hyperprolactinemia
were ruled out in all of the patients by ACTH-stimulated serum 17-
hydroxyprogesterone levels below 30 nmol/L (18) and basal serum PRL
concentrations below 24 mg/L.
Nine of the 19 patients, who had oligomenorrhea defined by men-
strual cycles longer than 36 days (19) fulfilled endocrine criteria for the
diagnosis of PCOS (2).
When the screening of the 19 hirsute patients described above de-
tected any variant, the analysis was extended to a larger group of
hyperandrogenemic hirsute patients with or without menstrual dys-
function (17) and to a group of 50 healthy women who did not have
hirsutism, acne, alopecia, or menstrual disturbances (20). Data from
these patients and controls regarding aspects of the pathophysiology of
hirsutism and hyperandrogenism different from those studied here have
been previously reported (17, 20).
The hospital ethics committee approved the study, and informed
consent was obtained from every patient and control.
Molecular genetic analysis
Genomic DNA was extracted from peripheral leukocytes following
the manufacturer’s instructions (Wizard Genomic DNA Purification Kit,
Promega Corp., Madison, WI). A broad screening was performed in the
19 patients for mutations in DAX-1, SF-1, and StAR genes, and in the
coding regions of CYP11A. We have not evaluated the variable tandem
repeat polymorphism in the promoter of CYP11A, as our previous study
in a large series of hirsute patients showed no association either with
hirsutism or hyperandrogenism (7).
DNA was used to amplify different portions of the genes described
above. PCR amplifications were performed using an automated ther-
mocycler (GeneAmp PCR System 2400, PE Applied Biosystems, Foster
City, CA).
The primers used for PCR amplification of each exon and intron-exon
boundaries of CYP11A and SF-1 genes and for amplification of the
59-regulatory regions of SF-1 gene (from 2246 to 155 in exon 1), DAX-1
(position 2194 to 198 in exon 1), and StAR gene (position 2950 to 2753,
which contains a putative SF-1-binding domain), were designed using
OLIGO 4.0 Primer Analysis Software (Molecular Biology Insights, Inc.,
Plymouth, MN). Primer sequences and PCR conditions are available
from the authors on request.
The primers used for the amplification of the two exons of DAX-1 and
for the promoter and seven exons of the StAR gene have been previously
described by others (21, 22).
Heteroduplex analysis (23) was used to detect variants, which were
identified by direct sequencing of PCR products using an ABI 310
automated sequencer (PE Applied Biosystems). Digestion by SphI or
MspI endonuclease restriction enzymes was used for the screening of
mutations that cause changes in target sites for these enzymes. Muta-
tions were confirmed by direct sequencing.
Variants present in more than 2% of the study population and in
similar proportions in patients and healthy controls were considered
common polymorphisms (24).
Results
The results are summarized in Table 1. We identified sev-
eral novel variants in the SF-1 and StAR genes and in
CYP11A. Analysis of SF-1 gene in the 19 hirsute patients
initially screened detected 2 different heterozygous muta-
tions. Two patients presented a G3C change in exon 4,
resulting in a Gly146Ala missense mutation. This mutation
creates a restriction site for SphI, and digestion by this en-
zyme was used for further testing. The presence of the
Gly146Ala mutation in 2 of 48 hyperandrogenic patients and
2 of 50 controls suggested that this variant is a polymorphism
(24).
A different patient, presenting with PCOS and increased
serum androgens of adrenal and ovarian origin, showed a
G3C change in exon 6, resulting in an Arg365Pro missense
mutation. Using digestion by MspI, which is prevented by the
Arg365Pro mutation, the latter was not found in any other
patient or control.
No mutations were found in the promoter region of
DAX-1 or in coding regions of the DAX-1 and StAR gene.
On the contrary, a C3T bp change at position 233 from
TABLE 1. Observed frequencies of the mutations found in the
SF-1 and StAR protein genes and in coding regions of CYP11A in
hyperandrogenic hirsute patients and healthy controls.
Gene Mutation
Observed frequencies [% (affected/total)]
Patients Controls
SF-1 (exon 4) Gly146Ala 4.2 (2/48) 4.0 (2/50)
SF-1 (exon 6) Arg365Pro 2.2 (1/45) 0.0 (0/50)
StAR (233) C3T 6.3 (3/48) 7.0 (3/43)
CYP11A (exon 3) Val179Ile 3.4 (1/29) 0.0 (0/50)
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the transcription start site of the StAR gene was identified
in 1 of the 19 patients initially screened. This mutation
results in a target site for MspI, and digestion by this
restriction enzyme was used to evaluate another 29 pa-
tients and 43 controls. A total of 3 patients and 3 controls
presented this variant, which therefore was considered a
polymorphism (24).
Finally, analysis of CYP11A-coding regions identified a
G3A change in exon 3, resulting in a Val179Ile missense
mutation. The mutation was found in 1 of 29 patients and was
not present in 50 nonaffected individuals. No other variants
were identified in other coding regions of CYP11A.
None of the affected patients or controls had more than
one of the variants described above.
Discussion
Recent data suggest that abnormalities in steroidogenesis
are a primary event in the pathogenesis of PCOS, affecting
nearly all of the enzymes involved in ovarian androgen syn-
thesis. Nelson et al. (5) found increased messenger ribonu-
cleic acid expression of the steroidogenic enzymes involved
in androgen synthesis in ovarian thecal cells from patients
with PCOS propagated in primary culture, including P450scc
and CYP17, together with increased enzyme activity of
P450scc, P450c17, 3b-hydroxysteroid dehydrogenase, and
17b-hydroxysteroid dehydrogenase type 5. On the contrary,
the expression of StAR was comparable to that in controls (5).
The increased activity of these enzymes resulted in increased
synthesis of androgens and steroid precursors (5). The per-
sistence of these findings after several passes in culture rules
out a significant influence of nonovarian factors in the in-
creased ovarian steroidogenesis of thecal cells from PCOS
patients (5).
Furthermore, using promoter constructs containing suc-
cessive truncations of the 59-flanking sequence of the human
CYP17 gene, these researchers have recently shown that the
region between 2235/2109 bp of the transcription site is
critical to the increased CYP17 messenger ribonucleic acid
expression and activity in PCOS thecal cells (25). Cotrans-
fection with SF-1 was required for the detection of basal and
forskolin-stimulated CYP17 promoter activity, in agreement
with the presence of SF-1 response elements in that region
(25).
Therefore, variants in the genes encoding the enzymes
involved in androgen synthesis and in those of their regu-
latory factors might be related to the up-regulation of ste-
roidogenic enzymes found in hyperandrogenism and hir-
sutism. As these factors are present in both the adrenal and
the ovary, their abnormalities might explain not only the
increased synthesis of androgens in the ovary, but also the
frequent finding of adrenal hyperandrogenism in hirsute and
PCOS patients (26).
The first and critical step in ovarian and adrenal steroi-
dogenesis is the conversion of cholesterol into pregnenolone.
This step is mediated by the actions of StAR and P450scc. The
genes encoding both proteins are influenced by several fac-
tors, including DAX-1 and SF-1, which are believed to play
a crucial role in the development and function of the adrenal
and gonads. The interaction between DAX-1 and SF-1 is
poorly understood. DAX-1 is a potent repressor of StAR gene
expression, blocking steroidogenesis (12) and also repressing
the transcriptional activity of SF-1 (27). SF-1 is generally
considered to be a transcriptional activator mediated by re-
cruiting coactivators; however, binding of DAX-1 to SF-1
turns SF-1 into transcriptional repressor, because DAX-1 is
able to recruit corepressors (27). The influence of DAX-1 and
SF-1 is not limited to the initial steps of adrenal and ovarian
steroidogenesis; it also modulates the activity of enzymes
such as P450c17 and 3b-hydroxysteroid dehydrogenase
(28, 29).
In the present study we screened the genes encoding these
factors and enzymes in women presenting with hirsutism
and increased serum androgen levels. The novel variants
found in our patients were not frequent enough to explain
the hyperandrogenism of these women.
The G146A variant in SF-1 gene and the C3T change at
233 of the StAR protein gene can be considered polymor-
phisms using the standard definition, as more than 2% of our
population is heterozygous for that locus (24) The small
proportion of patients affected and the similar proportion of
controls carrying the variant suggest that these are common
polymorphisms (30) and that the contribution of these vari-
ants to the pathogenesis of hyperandrogenism, if any, is
minor.
On the contrary, the variants found in exon 6 of the SF-1
gene and in exon 3 of CYP11A were not present in controls.
Comparison of the human and murine CYP11A sequences
revealed that mice present Ile at the equivalent position,
suggesting that the Val179Ile missense mutation found in one
patient probably has no important consequences for the func-
tion of this enzyme. Moreover, Val and Ile are similar amino
acids in terms of composition, polarity, and molecular vol-
ume, properties that correlate with the evolutionary ex-
changeability of protein residues (31, 32).
The Arg365Pro mutation found in one patient may have a
relevant impact on the function of SF-1, as an Arg is present
at equivalent positions of the murine, rat, and bovine SF-1
genes, and the introduction of a proline can affect the sec-
ondary structure of the SF-1 molecule.
Further work is needed to properly describe the Arg365Pro
missense mutation in exon 6 of SF-1. Examination of parental
genotypes is needed to evaluate the Mendelian inheritance
of this variant or the possibility of a de novo mutation. More-
over, functional studies using transcription assays after mu-
tagenesis in appropriate vectors will be required to evaluate
the impact of the Arg365Pro missense mutation on SF-1 ac-
tivity in different cell systems.
In conclusion, variants in DAX-1, SF-1, and StAR genes
and in coding regions of CYP11A are seldom found in
women with hyperandrogenic hirsutism. Moreover, the vari-
ants identified in our present study are either equally fre-
quent in patients and controls or are rare or conservative
changes and thus not likely to be significant contributors to
hyperandrogenism. Therefore, these genes do not appear to
play a major role in the pathogenesis of hirsutism and
hyperandrogenism.
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